JAK

The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.

Cat. No.	Product name	CAS No.	Purity
T11711	Jaspamycin	22242-96-2	98%
T11711	Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity. Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to th...
T12091	MM-589	2097887-20-0	98%
T12091	MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.
TN3541	Broussonin E	90902-21-9	98%
TN3541	Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathwa...
T15038	Momelotinib sulfate	1056636-06-6	98%
T15038	Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.
T11690	ITK inhibitor 2	1309784-09-5	98%
T11690	ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.
T2653	SB1317	1204918-72-8	98%
T2653	SB1317 is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
T67894	Butyzamide	1110767-45-7	98%
T67894	Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which pr...
T10424	AZ-3	2228908-91-4	98%
T10424	AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).
T12091L	MM-589 TFA	2097887-21-1	98%
T12091L	MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.
TN2775	2-Methoxystypandrone	85122-21-0	98%
TN2775	2-Methoxystypandrone displays an immunomodulatory effect in a cellular model, it blocks inflammatory responses by impairing NF-ÎºB signaling to limit the inflamm...
TN2002	Obovatol	83864-78-2	98%
TN2002	Obovatol has antioxidant, neuroprotective, antiinflammatory, antithrombotic and antitumour effects, it is a potent NF-κB inhibitors for Alzheimer's disease treat...
T22319	DTP3	1809784-29-9	98%
T22319	DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
T11714	JBJ-04-125-02	2060610-53-7	98%
T11714	JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities. JBJ-04-125-02 is a potent, muta...
TQ0061	CHZ868	1895895-38-1	98%
TQ0061	CHZ868 is a type II JAK2 inhibitor (IC50: 0.17 μM in EPOR JAK2 WT Ba/F3 cell).
T10009	JAK3-IN-7	1263774-57-7	98%
T10009	JAK3-IN-7 is an effective and selective JAK3 inhibitor (IC50 <0.01 μM) extracted from patent WO2011013785A1.
T15037	Momelotinib Mesylate	1056636-07-7	98%
T15037	Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.
TMA1743	Ergosterol peroxide	2061-64-5	98%
TMA1743	Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Fox...
T11708	JAK2-IN-4	1438284-00-4	98%
T11708	JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.
T2460	JAK 3 inhibitor IV	58753-54-1	98%
T2460	JAK 3 inhibitor IV is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutam...
TN4774	Physalin A	23027-91-0	98%
TN4774	Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling, it inhibits androgen-independent prostate canc...